GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Catalyst Biosciences Inc (FRA:HGF2) » Definitions » Quick Ratio

Catalyst Biosciences (FRA:HGF2) Quick Ratio : 2.88 (As of Sep. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Catalyst Biosciences Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Catalyst Biosciences's quick ratio for the quarter that ended in Sep. 2023 was 2.88.

Catalyst Biosciences has a quick ratio of 2.88. It generally indicates good short-term financial strength.

The historical rank and industry rank for Catalyst Biosciences's Quick Ratio or its related term are showing as below:

FRA:HGF2' s Quick Ratio Range Over the Past 10 Years
Min: 1.59   Med: 6.32   Max: 60.98
Current: 2.88

During the past 13 years, Catalyst Biosciences's highest Quick Ratio was 60.98. The lowest was 1.59. And the median was 6.32.

FRA:HGF2's Quick Ratio is not ranked
in the Biotechnology industry.
Industry Median: 3.58 vs FRA:HGF2: 2.88

Catalyst Biosciences Quick Ratio Historical Data

The historical data trend for Catalyst Biosciences's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Catalyst Biosciences Quick Ratio Chart

Catalyst Biosciences Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Quick Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 25.83 3.32 5.03 3.63 1.68

Catalyst Biosciences Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.40 1.68 2.05 2.73 2.88

Competitive Comparison of Catalyst Biosciences's Quick Ratio

For the Biotechnology subindustry, Catalyst Biosciences's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Catalyst Biosciences's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Catalyst Biosciences's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Catalyst Biosciences's Quick Ratio falls into.



Catalyst Biosciences Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Catalyst Biosciences's Quick Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Quick Ratio (A: Dec. 2022 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(26.626-0)/15.882
=1.68

Catalyst Biosciences's Quick Ratio for the quarter that ended in Sep. 2023 is calculated as

Quick Ratio (Q: Sep. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(4.809-0)/1.671
=2.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Catalyst Biosciences  (FRA:HGF2) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Catalyst Biosciences Quick Ratio Related Terms

Thank you for viewing the detailed overview of Catalyst Biosciences's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Catalyst Biosciences (FRA:HGF2) Business Description

Traded in Other Exchanges
N/A
Address
611 Gateway Boulevard, Suite 710, South San Francisco, CA, USA, 94080
Catalyst Biosciences Inc is a clinical-stage biopharmaceutical company. It mainly focuses on developing novel medicines to address serious medical conditions for individuals in need of treatment options. The company emphasizes product development efforts in the field of hemostasis and to develop valuable therapies for individuals with hemophilia. It is engaged in the clinical development of improved, next-generation subcutaneous prophylaxis using enhanced potency Factor VIIa and Factor IX variants.

Catalyst Biosciences (FRA:HGF2) Headlines

No Headlines